A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
Recruiting · Phase 1, Phase 2 · NCT05130437
Conditions: Propionic Acidemia
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-3927 (biological)
- Dates
- Started 2021-11-09; completion 2031-12-04
- Results posted
- Not yet
The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
From ClinicalTrials.gov, last updated 2026-03-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $1.3M in research payments for this study in 2025 (80 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hilary J. Vernon, M.D., PH.D. Pediatrics · Baltimore, MD
- Ayesha Ahmad, MBBS Medical Genetics · Ann Arbor, MI
- Dwight D. Koeberl Pediatrics · Durham, NC
- Margo S. Breilyn, MD Medical Genetics · Bronx, NY
- Can H. Ficicioglu, M.D. Medical Genetics · Philadelphia, PA
- Kevin E. Glinton, M.D. Medical Genetics · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Children's Hospital of Philadelphia, PA $702,841
- University of Michigan Health System, MI $144,379
- Baylor College of Medicine $143,274
- Duke University Medical Center $135,656
- Icahn School of Medicine at Mount Sinai $108,076
- Johns Hopkins University $17,688
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.